Comparison of the Hemodynamic and Hematologic Toxicity of a Protamine Variant after Reversal of Low-Molecular-Weight Heparin Anticoagulation in a Canine Model

Laboratory Animal Science

Volumn 47, Issue 2, 1997, Pages 153-160

  Hulin, Marc S ^a,b   Wakefield, Thomas W ^a   Andrews, Philip C ^a   Wrobleski, Shirley K ^a   Kadell, Amy M ^a   Downing, L Joseph ^a   Stanley, James C ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE; PROTAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DOG; FEMALE; HEART OUTPUT; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; MEAN ARTERIAL PRESSURE; NONHUMAN; THROMBOCYTOPENIA; TOXICITY TESTING;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD PRESSURE; CARDIAC OUTPUT; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; DOGS; FACTOR XA; HEMATOLOGIC DISEASES; HEPARIN, LOW-MOLECULAR-WEIGHT; OXYGEN CONSUMPTION; PEPTIDES; PROTAMINES;

EID: 0030992631     PISSN: 00236764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Landefeld, C. S., and P. Hanus. 1993. Economic burden of venous thromboembolism, p. 69-85, In S. Z. Goldhaber (ed.), Prevention of venous thromboembolism. Marcel Decker, Inc., New York.
2. Hirsh, J., and M. N. Levine. 1992. Low-molecular weight heparin. Blood 79:1-17.
3. Weitz, J., and J. Hirsh. 1993. New anticoagulant strategies. J. Lab. Clin. Med. 122:364-373.
4. Schafer, A. I. 1996. Low-molecular weight heparin: an opportunity for home treatment of venous thrombosis. N. Engl. J. Med. 334:724-725.
5. Wakefield, T. W., B. Lindblad, J. C. Stanley, et al. 1994. Heparin and protamine use in peripheral vascular surgery: a comparison between surgeons of the Society for Vascular Surgery and the European Society for Vascular Surgery. Eur. J. Vasc. Surg. 8:193-198.
6. Lindblad, B., A. Borgstrom, T. W. Wakefield, et al. 1989. Hemodynamic and hematologic alterations with protamine reversal of anticoagulation: comparison of standard heparin and a low-molecular weight heparin fragment. Eur. J. Vasc. Surg. 1:181-185.
7. Wakefield, T. W., P. C. Andrews, S. K. Wrobleski, et al. 1994. Reversal of low-molecular weight heparin anticoagulation by synthetic protamine analogues. J. Surg. Res. 56:586-593.
8. Stewart, W. J., S. M. McSweeney, M. A. Kellett, et al. 1984. Increased risk of severe protamine reactions in NPH insulin-dependent diabetes undergoing cardiac catheterization. Circulation 70:788-792.
9. Levy, J. H., I. M. Schwieger, J. R. Yaidan, et al. 1989. Evaluation of patients at risk for protamine reaction. J. Thorac. Cardiovasc. Surg. 98:200-204.
10. Horrow, J. C. 1985. Protamine: a review of its toxicity. Anesth. Analg. 64:348-361.
11. Teren, A. N., M. Lie, and U. Abildgaard. 1976. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb. Res. 8:413-416.
12. Larsen, M. L., U. Abildgaard, A. N. Teren, et al. 1978 Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238). Thromb. Res. 13:285-288.
13. Morel, D. R., E. Lowenstein, T. Nguyenduy, et al. 1988. Acute pulmonary vasoconstriction and thromboxane release during protamine reversal of heparin anticoagulation in awake sheep. Circ. Res. 62:905-915.
14. Morel, D. R., P. M. Mo Costabella, and J. F. Rittet. 1990. Adverse cardiopulmonary effects and increased plasma thromboxane concentrations following the neutralization of heparin with protamine in awake sheep are infusion rate-dependent. Anesthesiology 73:415-424.
15. Wakefield, T. W., C. B. Hantler, S. K. Wrobleski, et al. 1996. Effects of differing rates of protamine reversal of heparin anticoagulation. Surgery 119:123-128.
16. DeLucia, A., III, T. W. Wakefield, P. C. Andrews, et al. 1993. Efficacy and toxicity of differently charged polycationic protamine-like peptides for heparin anticoagulation reversal. J. Vasc. Surg. 18:49-60.
17. Ando, T., and S. Watanabe. 1969. A new method for fractionation of protamine and the amino acid sequences of salmine and three components of iridine. Int. J. Protein Res. 1:221-224.
18. Rosenberg, R. D. 1977. Chemistry of the hemostatic mechanism and its relationship to the action of heparin. Fed. Proc. 36:10-18.
19. Olson, S. T., and J. D. Shore. 1982. Demonstration of a twostep reaction mechanism for inhibition of alpha-thrombin by antithrombin III and identification of the step affected by heparin. J. Biol. Chem. 257:14891-14895.
20. Wakefield, T. W., P. C. Andrews, S. K. Wrobleski, et al. 1995. Effective and less toxic reversal of low-molecular weight heparin anticoagulation by a designer variant of protamine. J. Vasc. Surg. 21:839-849.
21. Wakefield, T. W., P. C. Andrews, S. K. Wrobleski, et al. 1996. A [+18RGD] protamine-variant for nontoxic and effective reversal of conventional heparin and low-molecular weight heparin anticoagulation. J. Surg Res. 63:280-286.
22. Levine, M., M. Gent, J. Hirsh, et al. 1996. A comparison of low-molecular weight heparin administration primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N. Engl. J. Med. 334:677-681.
23. Koopman, M. W., P. Prandoni, F. Pionella, et al. 1996. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular weight heparin administered at home. N. Engl. J. Med. 334:682-687.
24. Hird, R. B., F. G. Spinale, K. W. Hewett, et al. 1994. The direct effects of protamine sulfate on myocyte contractile processes. J. Thorac. Cardiovasc. Surg. 108:1100.
25. Hird, R. B., T. W. Wakefield, R. Murkherjee, et al. 1995. The direct effect of protamine sulfate on myocyte contractile processes: cellular and molecular mechanisms. Circulation 92(Suppl. II):II-433-II-446.
26. Ruoslahti, E., and M. D. Pierschbacher. 1987. New perspectives in cell adhesion: RGD and integrins. Science 238:491-496.